initi coverag
initi overweight excit next chapter
invest summari initi coverag vertex overweight
rate price target think vertex remain
market share leader cystic fibrosi treat major market
near pivot readout best-in-class cystic fibrosi triplet data late
year/earli next year therefor think data stori turn
commerci execut around market triplet regimen think
next pipelin cystic fibrosi also believ vertex
robust intern discoveri engin allow develop mani novel
blockbust therapi in-hous report focu detail analysi
asset vertex/crispr collabor
believ vertex maintain sustain leadership cystic fibrosi
confid success peak estim total cystic fibrosi
revenu assum treat major patient
ww cf market investor confid upcom
readout tripl regimen good translat
efficaci
think symdeko triplet launch drive signific revenu
ep growth vertex symdeko launch us eu current estim
triplet could market sometim estim two
product could add total cf revenu grow
believ could promis product
pipelin incorpor peak sale base case think
beta thalassema sickl cell market opportun sale could
peak studi underway europ product remain clinic hold
us although unsur exactli reason hold would assum
regul want move cautious care new modal
thought preclin data encourag compani saw fetal
hemoglobin increas high edit rate edit
slightli lower vs consensu revenu
compani total cf franchis look model think
consensu aggress ex-u orkambi ramp sinc franc uk still
base case ask vertex also model modest sale
symdeko ex-u mostli germani sinc want cautiou toward timelin
take vertex secur reimburs
disclosur section may found page
initi coverag vertex
life post cystic fibrosi next chapter excit
vertex overweight price upsid
vertex global biotechnolog compani invest scientif innov creat
transform medicin peopl seriou life-threaten diseas
believ vertex robust intern discoveri engin
allow develop mani novel blockbust therapi in-hous
think vertex remain market share leader cystic fibrosi
treat major market also believ next
month begin see what next pipelin post
competitor cf could becom real threat
watch galapagoss falcon studi think expect success
furthermor commerci threat vertex low
key program focu post cf
next month think could get better visibl excit
pain develop pathway forward neuropath pain data earli
crispr beta-th sickl cell gene therapi collabor potenti poc
antitrypsin could enter clinic soon -- genet diseas affect liver
lung caus mis-fold protein think fit excel vrtx
focal segment glomerulosclerosi fsg early-stag program
compani recent start discuss
event watch
exhibit vertex catalyst drug franchis next monthsvrtx relev eventdrugvrtx readout teza/ivacyst fibrosisl readout teza/ivacyst fda tripl combocyst fibrosismid tripl data falcon corrector cystic data neuropath pain proof concept data fsgsnew assetsrar cantor fitzgerald research vertex product revenuessourc cantor fitzgerald vertex pharmaceut oper metric perform
valuat use probability-adjust dcf valu vertex share assum discount rate model revenu
assum termin valu roughli vertex valuat base termin valu reflect compani intern engin
compani report factset research cantor fitzgerald research price
holdersmarket valu mm outt row price associ vanguard group manag research fund research manag co world fund manag manag co invest associ invest manag rate price price vrtx-u last outstand cap valu day interest cover price current market price vertex pharma comp estim vs consensu
rate share overweight price target
exhibit vertex comp compspricemarket cap ev sale ep price-to-earnings factset price vertex quarterli estim cantor vs sale sale cantor fitzgerald research factsetexhibit vertex annual estim cantor vs sale sale cantor fitzgerald research factset septemb
vertex thesi want hetmin success true intern capabl
leav compani mani option post cystic fibrosi cf
launch overweight rate price target
sustain leadership cf think vertex remain domin player cystic fibrosi
high convict triplet cf franchis like posit upcom phase cystic fibrosi
studi tripl combin
potenti big cf launch next year think symdeko tripl combin
launch drive upsid earn
 engin find new asset post cf although think much cystic fibrosi stori
play stock excit what next vertex believ compani
best-in-class research discoveri capabl
vertex overview market leader cystic fibrosi next chapter come
vertex base busi mostli focus treatment cystic fibrosi cf
vertex domin market share cystic fibrosi us europ current sell
current compani expos cystic fibrosi product pill
vertex develop invest new modal new indic synergi cystic
exhibit vertex revenu cystic fibrosissourc cantor franchiseexhibit vertex product revenuessourc cantor fitzgerald septemb
chang sinc prior coverag much still bullish cf compani
think vertex continu execut well cystic fibrosi market
estim vertex take cf market see earn growth
model broken hetmin symdeko model granular drug
focus what next vertex beyond cf due dilig around potenti pipelin
program could emerg report like crispr antitrypsin pain
think proprietari report
also sat recent vertex manag includ new cfo
emerg larg cap univers vertex attract growth profil
vertex show top-lin growth peer bottom line growth closer in-lin
consensu vertex project top bottom-lin compound-annual-growth-rate
project vertex top- bottom-lin compound-annual-growth-rate period
exhibit rel revenu compound-annual-growth-rate emerg larg cap stockssourc factset cantor rel ep compound-annual-growth-rate emerg larg cap stockssourc factset cantor septemb
howev particularli cheap ev/sal surpris us
compar emerg larg cap ev/sal earn multipl variabl earli growth
vertex trade premium peer think research discoveri strong
help provid support premium
exhibit rel valuat emerg larg cap stock ev/sal
exhibit rel valut emerg larg cap stock ev/salessourc ev/sal reflect vertex past present futur what cf come focu though
still await data launch like biggest cf drug
near-term focu remain cystic fibrosi slowli shift program well
vertex oper gear cystic fibrosi franchis think time
product emerg portfolio beyond cf
exhibit cantor reflect stand storywher come past month tripl data readout impress symdeko approv earli investor discuss around competitor mostli galapago glpg much back forth reimburs ex-u orkambi current pelcian competit studi second gen corrector readout look less robust tripl studi enrol rapidli launch perform well beat expect still much back forth reimburs ex-u orkambiwher go await tripl data late expect compani launch tripl could learn vertex plan go forward crispr studi underway expect compani remain activ partnership could see think return cash sharehold type way due strong cash flow generationsourc cantor fitzgerald research expect high tripl data vertex expect low falcon
competitor trial risk think catalyst
overview vertex catalyst focus next month
tripl data success almost fulli bake expect
falcon studi run galapago glpg cover think expect lower
see pelican gen corrector studi
exhibit vertex catalyst drug franchis next monthsvrtx relev eventdrugvrtx franchisereadoutstock importancecantor readout teza/ivacyst fibrosisl high think trial work safeti readout teza/ivacyst high think trial work safeti focusfil fda tripl combocyst fibrosismid import think could approv vertex breakthrough design program could get approv sometim viewcompetit tripl data falcon corrector cystic said fulli screen timelin data neuropath pain think studi import vertex determin strateg direct programearli proof-of-concept data fsgsnew assetsrar cantor fitzgerald research septemb
investor vertex debat view
debat high level view
risk triplet data expect high alreadi
feel confid efficaci translat
look safeti profil triplet vertex coupl triplet de-risk
glpg falcon studi show efficaci similar vertex happen
dont think falcon show data competit vertex triplet
think stock would pressur share worth valuat
current assum vertex treat market leav room competitor
what next post cystic fibrosi vertex relat pipelin
think vertex capabl discov in-hous give flexibl
sinc a/deal absolut necessari
watch crispr collabor studi beta-thalassemia sickl cell
pain program could emerg like antitrypsin focal segment
base case valuat use probabl adjust dcf analysi
month price target rate overweight
use probability-adjust dcf analysi valu vertex share model cash flow
assum discount rate assum termin growth rate reflect compani
vertex tax base work free cash present valu growth termin per septemb
risk clinic success triplet program phase
risk thesi clinic failur competit achiev revenu estim
lack triplet success
view outright failur trial highli unlik scenario unexpect safeti
signal lower expect efficaci base could put pressur share
posit galapago glpg cover cf data would like present downsid surpris
vertex share dont think glpg competit risk expect
model vertex take share market leav room competitor
pipelin failur stall
think post triplet data investor begin look concret develop plan
 engin
program credit signific safeti event would headlin neg share
event franchis
vertex tripl combo like signific improv cf patient add anoth
patient group elig vertex medicin
preclin model level cftr correct higher triplet vs approv regimen
patient
het/min triplet
think triplet like
volum sec
homozyg gate mutat
bar certainli higher
kalydeco greater effect
exhibit vertex cf therapi associ expans cf populationsourc septemb
think vertex sustain competit advantag cystic fibrosi
mani competitor cystic fibrosi
galapago glpg cover remain cf develop area get question
vertex closest competitor timelin think
think glpg platform meaning behind vertex point yet move
phase wherea expect vertex data late tripl regimen
exhibit diseas modifiy therapi cystic fibrosi daili discoveri correctorglpg repair repair cftrsourc compani data confid data look pretti similar saw phase
reason confid though think everyon confid well make risk/reward
bad event
preclin model show increas cftr transport almost back corrector level
prior clinic studi phase data look fairli similar happen phase
biggest unknown triplet safeti profil vertex studi multipl triplet
phase like mitig risk
exhibit phase data triplet cf combinationssourc vertex septemb
preclin evid support clinic efficaci
cystic fibrosi transmembran conduct regul cftr protein direct chlorid channel transport
vertex tripl dramat increas percent normal cftr vs orkambi initi
refer kalydeco increas cftr level orkambi less tripl
think vertex develop novel corrector goal achiev carrier level cftr
exhibit preclin cftr level hbe cellssourc vertex gener cf medicin vertex meaning transform abil disease-
next gener vertex combin chang higher kalydeco
know compar kalydeco orkambi patient experi variabl mani
reason one key level chang measur expir
exhibit compar efficaci absolut differ cf therapiessourc vertex cantor fitzgerald daili daili though investor expect lower falcon studi remain focu compar
falcon galapago studi triplet run small cohort uk
think expect studi least chang baselin
similar vertex tripl show het/min
base vertex comment gener triplet also improv homozyg patient robust
way look trend falcon homozyg studi
exhibit galapago design falcon studi cystic fibrosi triplesourc galapago septemb
vertex second-gener corrector look efficaci
cross-trial comparison includ illustr point
look addit second corrector vertex galapago compound
think vertex second corrector look effect monotherapi
compar rel efficaci vs orkambi fev
exhibit illustr ad efficaci ad second correctorsourc vertex cantor fitzgerald think vertex meaning lead glpg triplet even data
reason believ galapago competit threat regardless falcon
base data sure triplet robust
cautiou around glpg program none agent studi
think vertex get medicin market make enrol difficult
competitor
could also slow studi design flexibl regul sinc therapi
think glpg compound need extens safeti readout even compani start
phase sometim aggress
triplet import life cycl manag perspect would give
major platform ip mid
patent life next gener corrector last mid
convers vertex
would also expect deuter kalydeco ip protect around time-frame
though compani said
exhibit patent exclus cf productsourc vertex gener correctorseuu think symdeko launch robust sinc improv efficaci
estim slightli ahead consensu near-term
symdeko approv feb us approv ex-u
symdeko doesnt chest tight earli treatment orkambi
howev symdeko could replac tripl combin approv
expect think investor look total cf guidanc
product consensu hard track due transit triplet handl legaci product
review consensu product estim hard use guid think expect
symdeko launch estim focu
also cf total revenu guidanc anoth focu track perform
exhibit cf total revenu cantor vs consensussourc factset cantor fibrosi revenues- cantorcyst fibrosi revenues- factset consensu septemb
vertex develop medicin in-hous beyond cf support view vertex
sustain develop therapeut futur
view support belief compani best-in-class biotech univers
though ancient histori vertex hcv franchis develop in-hous sold peak
vertex partnership merck kgaa medicin develop flu oncolog
dont model revenu royalti flu oncolog
exhibit novel product develop vertex beyond cystic fibrosisvertex drugdiseas categorymechan actionpartnerteleprevirhcvproteas inhibitorregion cap snatch activti influenza viral polymerasej jlexivahivproteas inhibitorgskagenerasehivproteas channel kinas inhibitormerck kgaasourc vertex cantor fitzgerald dont think vertex current get much explicit credit pipelin fair
learn
asset develop support belief compani best-in-class biotech
rest report discuss quick review vertex pipelin help familiar investor
inform begin read
captur pipelin late-stag preclin work rare diseas may
exhibit vertex pipelinevertex drugdiseas categorymechan replic influenza spinal cord injuryrho vertex cantor fitzgerald septemb
vertex crispr move clinic beta thal sickl cell
compani enter year collabor
look address genet caus cf hemoglobinopathi like sickl cell beta thalassemia
lead program hemoglobinopathi opted-in late
think vrtx/crispr collabor exampl vertex expand
modal synergi rare diseas
gain exposur scientif hot crispr-
strateg collabor establish
vertex exclus right licens target compani paid
up-front
research develop revenu split evenli hemoglobinopathi treatment sickl cell
beta thalassemia
gene-edit technolog could allow greater precis correct
disease-caus issu genet sourc
crispr one lead player gene edit along edita intellia
technolog allow alter dna sequenc modifi gene function
crispr special stretch dna
enzym act like pair molecular scissor cut strand dna
typic guid bit rna code tell scissor
deriv natur defens mechan bacteria archaea
exhibit way work nutshellsourc crispr septemb
beta thalassemia caus error gene hemoglobin
hemoglobin respons carri oxygen within red blood cell
beta-thalassemia caus mutat give rise insuffici express beta globin
insuffici express lead anemia need regular blood transfus
exhibit thalassemia impact red blood cellssourc nih joshya/shutterstock com septemb
ex-vivo gene edit approach up-regul fetal hemoglobin
someon fetal hemoglobin high life person typic asymptomat mild
ctxx use gene edit up-regul express gamma globin protein hemoglobin
subunit typic present newborn infant
hemoglobin contain gamma globin instead beta globin protein call fetal hemoglobin hbf
fetal hemoglobin oxygen-carri hemoglobin present birth normal replac
adult form
exhibit fetal hemoglobin diseas pathologysourc crispr septemb
key gene prevent fetal hemoglobin transform adult form
preserv fetal hemoglobin transform reduc symptom
gene repress fetal hemoglobin product gene mutat
allow fetal hemoglobin product continu allow asymptomat mild phenotyp
data show method edit blood stem cell remov beta thal
exhibit gene affect fetal hemoglobin levelsourc bauer et al blood journal septemb
disrupt erythroid enhanc use
key actor repress fetal hemoglobin
work cut remov brake fetal hemoglobin product
exhibit workssourc crispr upregul fetal hemoglobin engraft mice
mice edit lead increas hbf fetal hemoglobin
exhibit preclin studi use micesourc crispr septemb
american societi hematolog meet
present dr lundberg cso crispr
hematopoiet stem cell edit target site
cell edit copi gene led express level
hemoglobin threshold significantli lower symptom
exhibit globin mrna ratio post gene edit patient samplessourc crispr sickl cell diseas also due error gene hemoglobin
hemoglobin respons carri oxygen within red blood cell
sickl cell diseas lead red blood cell rbc abnorm shape look like sickl
due mutat hemoglobin gene patient atyp hemoglobin molecul call
sickl cell rbc sticki rigid mean prone get trap small vessel
block blood reach certain part bodi
mutat lead anemia joint pain enough red blood cell lung liver kidney
damag
exhibit sickl cell diseas impact red blood cellssourc nih daryl leia nhgri beta-th studi underway dont know compani disclos
result studi europ
vertex note compani clinic trial approv uk canada
exhibit eu trial modifi hhpscstreatment populationtransfus depend beta thalassemiadesignopen labeldosesivsampl durationsingl doseprimari endpointsafeti efficaci singl dosesecondari endpointquantifi edit allel peripheri blood leukocyt bone marrow cellsassess product hbf post infusioneffect diseas specif eventsinclusiondocu homozyg b-thal contracept must use least mo infus karnofski perform statu allo-hemotopoiet stem cell transplant advanc liver diseasetri enter site plan canada itali uk eudract full trial eu registerphas studi safeti efficaci singl dose autolog modifi human hematopoiet stem progenitor cell hhspc subject transfus depend beta thal us clinic hold vertex crispr work fda question
vertex note compani clinic trial approv uk canada
call manag note first gene edit trial outsid cancer
got increment color manag meet
fda like appropri cautiou conserv around novel therapi
howev could get proof-of-concept eu trial next month
estim beta thal sickl cell could opportun
crispr estim live birth annual sickl cell us preval patient
crispr estim incid beta thalassemia birth annual total preval
us eu
assum probabl success base case
vertex hemoglobinopathiesalethia young cantor cell adjust thalassemia us depend patient market gross cell us cell patient market gross think vertex posit make decis pain sometim
program current unpartn
design block pain signal inhibit sodium channel known
studi three pain popul acut chronic neuropath pain
speak manag think view data compel though
sinc program realli vrtx wheelhous think neuropath pain studi read
earli decid asset strateg
think asset isnt opioid opioid-lik efficaci could attract pain
phase readout feb dont think data present yet
acut pain trial hit primari endpoint stat sig chang sum pain intens
differ first hour treatment
compar placebo hydrocodon acetaminophen
exhibit acut pain data post bunionectomi treatment treatment stat sig vs placebo compar vicodin vertex antitrypsin program may move clinic soon vertex think
protein fold someth vertex well
program current unpartn
genet disord could result lung liver diseas
caus mutat gene
anoth protein-fold diseas misfold bad actor
protein protect lung liver damag
sometim patient initi diagnos asthma patient
diseas respond asthma medicin
think protein fold someth vertex well could make nice
complementari program vertex
mani symptom express lung dysfunct
exhibit biolog alpha anti-trypsian deficiencysourc journal hepatolog loma et al anoth program vertex discuss focal segment glomerulosclerosi fsg
idiopath diseas typic diagnos renal biopsi
kidney million tini filter call glomeruli
glomeruli damag scar protein begin leak urin proteinuria
word focal segment suggest glomeruli certain section scar
jeff leiden md phd dr leiden chairman presid chief execut offic vertex
pharmaceut receiv ph degre honor univers
chicago physician scientist last year dedic career improv
live peopl seriou diseas experi span aspect biotech
ian smith ian smith join vertex novemb vertex chief oper offic mr smith
hold respons core function vertex includ account financ strateg sourc
corpor busi develop corpor strategi global facil oper global
inform system corpor estat develop pharmaceut oper investor
david altshul md ph david altshul execut vice presid global research chief
scientif offic dr altshul lead vertex research effort aim
discov new medicin treatment cf seriou diseas overse
compani three research site boston san diego oxford uk
cf sale us orkambi symdeko symdeko us residu symdeko residu function symdeko hetmin hetmin cf franchis vertex cystic fibrosi summari sale
yr yr mutat year mutat year function year yr yr mutat year mutat year function year yr yr mutat year mutat year function year kalydeco franchis kalydeco salesorkambi salesorkambi year year year year year year year year year orkambi franchis orkambi salessymdeko sale orkambi discontinuationssymdeko year year year year year year year year year symdeko franchs sale ww hetmin franchis vertex cystic fibrosi summari patient
patient eligibleu ww mutat mutat ww mutat mutat elig homozyg orkambi homozyg orkambi homozyg orkambi homozyg orkambi homozyg orkambi homozyg orkambi elig elig vertex ww mutat us kalydeco ww mutat row kalydeco us orkambi row orkambi hetmin hetmin cf franchis vertex incom statement annual
cantor biotech vertex incom statementalethia pipelin opportun net product royalti collabor total revenu expens net product net product net product sg expens incom oper expens incom incom effect tax incom ep ep dilut growth ep ep dilut vertex incom statement quarterli
cantor biotech vertex incom statementalethia pipelin opportun po non- net product royalti collabor total revenu expens net product net product net product sg expens incom oper expens incom incom effect tax incom ep ep dilut growth ep ep dilut vertex balanc sheet
cantor biotech vertex balanc sheetbal cash short-term market account receiv prepaid expens current current plant equip asset long term term leas oblig current current current revenu exclud current term leas oblig exclud current financ leas oblig exclud current tax long-term non-controlling interest liabil vertex statement
cantor biotech vertex statement operationsnet non-oper item depreci account expens expens investingcapit expenditur net cash sale intang market sale market financingdebt capit leas construct financ leas septemb
vertex global biotechnolog compani invest scientif innov creat transform medicin peopl seriou
life-threaten diseas
